A U.S. Congressman on a key investigating subcommittee is buying two healthcare stocks that have fallen over 50% this year. He recently made a significant purchase in Centene (CNC), which is heavily exposed to recent Medicaid funding cuts. The same politician also bought shares of United Health Group (UNH), another major insurer impacted by the same news. The investment thesis suggests this insider may believe the market's fears are overblown and is buying these stocks at a deep discount. This is a high-risk strategy, but it follows a potentially informed politician betting on a recovery for the healthcare insurance sector.

Centene (CNC)

• A U.S. Congressman from North Carolina, Rep. Tim Moore, recently disclosed a $265,000 purchase of Centene stock.
• Centene (CNC) is a large Fortune 500 healthcare company whose stock has fallen more than 50% since the start of the year.
• The primary reason for the stock's decline is a new bill that slashed $1 trillion in Medicaid funding. Centene is particularly vulnerable as it derives 62% of its revenue from Medicaid.
• Interestingly, Rep. Moore is the vice chair of the Subcommittee on Financial Oversight and Investigation, which is actively investigating potentially fraudulent Medicaid billing practices.

Takeaways

• The podcast speculates that Rep. Moore's purchase could be a bullish signal. His position on the investigating subcommittee gives him potential access to non-public information.
• The theory is that Rep. Moore may believe the investigation will not be as damaging to Centene as the market fears, and he is buying the stock at a discount before this information becomes public.
• This is a high-risk, "falling knife" investment strategy. The potential insight is that a key politician is betting on a recovery, suggesting the negative sentiment around CNC may be overblown.

United Health Group (UNH)

• In addition to Centene, Rep. Tim Moore also disclosed two separate purchases of United Health Group (UNH) stock.
• UNH is another major healthcare company that has seen its stock decline by more than 50% year-to-date, largely due to the same $1 trillion cut in Medicaid funding.
• The context of Rep. Moore's influential role on the subcommittee investigating Medicaid also applies directly to UNH.

Takeaways

• Similar to the Centene trade, Rep. Moore's purchases of UNH are seen as a potentially bullish indicator from an informed individual.
• The investment thesis is that he may be "front running" a positive outcome from the Medicaid investigation, which could cause the stock to bounce back from its lows.
• The podcast frames this as a speculative opportunity, questioning if it's "worth trying to catch the falling knife." This suggests that while there could be a significant upside if the thesis is correct, the risk is also substantial.